Does changing the reference genome from hg38 to T2T-CHM13 affect mapping over clinically relevant variants?
We show that the T2T-CHM13 reference genome reduces bias in human sequence analysis with implications for variant discovery and clinical genomics.biorxiv.org/content/10.64898…
· Reference genome assembly choice impacts the detection of clinically relevant variants , including pathogenic variants in BRCA1 gene
1
18
In light of our results, we support the implementation of the T2T-CHM13 reference for the improvement of sequencing data analyses in the clinical genomic setting.
DemichelisLab (@FrancescaBZNY) @CIBIO_UniTrento @UniTrento
18
Yari Ciani retweeted
Favorite study!
Germline-somatic tandems dictate cancer subtypes, provide clinical insights, and fuel molecularly informed studies.
Kudos: Blerta Stringa,
@Paola_Gasperini, Alessandro Alaimo, and
@LunardiLabCIBIO (co-last a!)
@NimaSharifiMD
doi.org/10.1158/2159-8290.CD…
@UniTrento
Yari Ciani retweeted
🚨 Excited to announce our new paper, “SpikeFlow: Automated and Flexible Analysis of ChIP-Seq Data with Spike-in Control”, now online in NAR Genomics and Bioinformatics! 🚨
🔗 academic.oup.com/nargab/arti…
@LabChiacchiera @aromanel
Yari Ciani retweeted
🔥Post-doc position open🔥 at the Demichelis laboratory @UniTrento
⏳ application by August 31st!
👉 more info evitasociety.org/index.php/a…
#oncosome #prostatecancer #evitians @CaterinaNardel1 @FrancescaBZNY
In our research group at DemichelisLab (@FrancescaBZNY) we are currently working on plasma-derived EVs from prostate cancer patients: works like the one from @IcasanovaSalas are a treasure trove both for biomarker discovery/validation and for generating new hypotheses.
1
1
72
Many thanks to @CancerCell for the opportunity, to @FrancescaBZNY and @CaterinaNardel1 for the invaluable help and pristine writing, and @AIRC_it for the financial support.
62
Casanova-Salas and colleagues analyze cfDNA, EV-DNA, and EV-RNA in prostate cancer longitudinal cohorts and identify signals of tumor adaptation to androgen receptor signaling inhibitors or taxanes treatment. doi.org/10.1016/j.ccell.2024…
74
I had the honor of writing a preview of the article published by @ICasanovaSalas et al. in the latest issue of @Cancer_Cell . doi.org/10.1016/j.ccell.2024…
Yari Ciani retweeted
🥂🙌 A new doctor, Thomas Cantore, Ph.D. @cantore_thomas in the Computational and Functional Oncology DemichelisLab! #PRODE
@CIBIO_UniTrento
@paola_gasperini @YariCiani
@MariannKruithof
@NCIEytanRuppin
Yari Ciani retweeted
Happy 2024! #EVClub resumes with a study of #ExtracellularVesicles and #cfDNA to detect #HER2 positivity in #BreastCancer
Need the login? Sign up: surveymonkey.com/r/EVClubISE…
@IsevOrg @IsevComms @ISEV_Journals @LabWitwer @EVItaSociety isevjournals.onlinelibrary.w…
Yari Ciani retweeted
I am beyond excited to see our work out in @CD_AACR . We established a targeted sequencing assay to non-invasively monitor treatment resistance in advanced prostate cancer. Want to know more? Let’s take a short walk 👣
aacrjournals.org/cancerdisco…
Yari Ciani retweeted
👏Read in #JExBio👏These authors developed and assessed ONCE (One Aliquot for Circulating Elements), an approach for the isolation of EVs and cfDNA from a single aliquot of blood. #liquidbiopsies Read it here 👉onlinelibrary.wiley.com/doi/…
We currently apply the methodology also to metastatic prostate cancer patients' liquid biopsy to study treatment resistance as part of the #PRIME program funded by @AIRC_it @CR_UK More to come!
@FrancescaBZNY @CaterinaNardel1 @vera_mugoni @IsevOrg @DoloresDiVizio @CIBIO_UniTrento
1
2
79
Full paper: doi.org/10.1002/jex2.108
40
















